Skip to main content
Premium Trial:

Request an Annual Quote

Oxford GlycoSciences, Cambridge Antibody Form Protein Microarray Alliance: Sep 12, 2000

OXFORD, UK, Sept 12 - Oxford GlycoSciences (LSE: OGS) of Oxfordshire, UK, and Cambridge Antibody Technology (LSE: CAT) of Melbourn, UK, said Tuesday that they are cooperating to develop protein chip technology that will identify proteins by applying antibody-based microarrays.

First OGS’s human protein libraries and CAT’s human antibody libraries will be analyzed so that paired proteins and antibodies can be selected. Then the companies will use OGS’s protein microarray prototype format to develop new microarrays.

The companies want to build a new line of protein detection technology with the speed, throughput, and sensitivity needed to assist the development of research tools, diagnostics, and novel therapeutics. OGS and CAT will fund their respective research contributions.

Michael Kranda, CEO of OGS said, “With the Human Genome map in hand the spotlight has shifted to proteins, proteomics, and antibody technology. The CAT/OGS Protein Chip project will focus on combining our expertise to explore the next generation of high-throughput proteomics technology. We see the field of analytical proteomics maturing similarly to genomics.”  

Kranda added that the alliance will provide access to CAT’s high-throughput antibody technology to shift the OGS prototype microarrays to an industrial scale for developing protein chips as screening and diagnostic tools.  

David Chiswell, CEO of CAT said, “Understanding the expression, processing, modification, and activity of proteins is fundamental to the development of revolutionary diagnostics, prognostics, and therapies for human disease management. We at CAT believe that antibody-based microarrays will be a core tool for unlocking this understanding.”

OGS, a proteomics-based drug discovery and development company, has proteomics collaborations with Bayer, DuPont’s (NYSE: DD) Pioneer Hi-Bred, Merck (NYSE: MRK), and Pfizer (NYSE: PFE). The company also has a joint venture with Incyte Genomics (Nasdaq: INCY).

CAT uses its proprietary technologies in human monoclonal antibodies for drug discovery and development.   Four human therapeutic antibodies developed by CAT are at various stages of clinical trials.

CAT’s has linsing and collaboration deals with Eli Lilly (NYSE: LLY), Pfizer, BASF Pharma, Genentech, ICOS Corporation (Nasdaq: ICOS), Genetics Institute, American Home Product’s (NYSE: AHP) Wyeth-Ayerst Laboratories, Human Genome Sciences (Nasdaq: HGSI), AstraZeneca, and Pharmacia (NYSE: PHA).

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.